Drug Trial Radar · NCT07828353
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Regend TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
PlaceboBiological
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up.
REGEND001Biological
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)Time frame: Week 52 after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.